Vivek Badwaik1, Yawo Mondjinou1, Aditya Kulkarni1, Linjia Liu1, Asher Demoret1, David H Thompson2. 1. Department of Chemistry, Multi-Disciplinary Cancer Research Facility, Bindley Bioscience Center, 1203 W. State Street, West Lafayette, Indiana 47907, USA. 2. Department of Chemistry, Multi-Disciplinary Cancer Research Facility, Bindley Bioscience Center, 1203 W. State Street, West Lafayette, Indiana 47907, USA. davethom@purdue.edu.
Abstract
A family of cationic Pluronic-based polyrotaxanes (PR(+)), threaded with 2-hydroxypropyl-β-cyclodextrin (HPCD), was synthesized for pDNA delivery into multiple cell lines. All PR(+) formed highly stable, positively charged pDNA complexes that were < 250 nm in diameter. The cellular uptake and pDNA transfection efficiencies of the PR(+):pDNA complexes was enhanced relative to the commercial transfection standards L2K and bPEI, while displaying similar or lower toxicity profiles. Charge density and threading efficiency of the PR(+) agent significantly influenced the colloidal stability and physical properties of the complexes, which impacted their intracellular transfection efficiencies. Taken together, our results suggest that HPCD: Pluronic PR(+) can be used as potent vectors for pDNA-based therapeutics.
A family of cationic Pluronic-based polyrotaxanes (pan> class="Chemical">PR(+)), threaded with 2-hydroxypropyl-β-cyclodextrin (HPCD), was synthesized for pDNA delivery into multiple cell lines. All PR(+) formed highly stable, positively charged pDNA complexes that were < 250 nm in diameter. The cellular uptake and pDNA transfection efficiencies of the PR(+):pDNA complexes was enhanced relative to the commercial transfection standards L2K and bPEI, while displaying similar or lower toxicityprofiles. Charge density and threading efficiency of the PR(+) agent significantly influenced the colloidal stability and physical properties of the complexes, which impacted their intracellular transfection efficiencies. Taken together, our results suggest that HPCD: Pluronic PR(+) can be used as potent vectors for pDNA-based therapeutics.
Authors: Mark E Davis; Jonathan E Zuckerman; Chung Hang J Choi; David Seligson; Anthony Tolcher; Christopher A Alabi; Yun Yen; Jeremy D Heidel; Antoni Ribas Journal: Nature Date: 2010-03-21 Impact factor: 49.962
Authors: Vivek D Badwaik; Emilio Aicart; Yawo A Mondjinou; Merrell A Johnson; Valorie D Bowman; David H Thompson Journal: Biomaterials Date: 2016-01-08 Impact factor: 12.479